Annabella Amatulli

Head of Regulatory

Annabella Amatulli is a recognized expert in global regulatory affairs with over 15 years of experience in the pharmaceutical and biopharmaceutical industry. She currently serves as head of regulatory affairs at Enterprise Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapies for respiratory diseases. Here, she leads regulatory strategy for the company’s pipeline, including the Phase 2 clinical program for ETD001 in cystic fibrosis. Earlier in her career, she gained valuable experience in senior regulatory roles at Janssen-Cilag (Johnson & Johnson), Schering-Plough, and Mylan. Her regulatory track record spans multiple continents and encompasses a wide range of achievements: Orphan Drug Designations, Fast Track and Breakthrough Therapy designations, Pediatric Investigation Plans, global early access programs, IND submissions, and successful marketing authorizations for rare disease therapeutics. Annabella holds a bachelor’s degree in pharmaceutical biotechnology from the University of Milan and a master’s degree in biology from the University of Milano-Bicocca. Currently she is the President of HBA Milan.